Articles tagged with Myasthenia Gravis
A phase 3 randomized controlled trial found that gefurulimab significantly improved clinical benefits for adults with generalized myasthenia gravis, resulting in meaningful improvements in daily living and muscle strength scores. Most side effects were mild and similar between treatment and control groups.
A study published in Neurology found that pregnancy is not associated with an increased risk of serious flare-ups or new symptoms of myasthenia gravis. In fact, nearly 90% of women experienced no hospital admissions related to the disease after giving birth.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
A study using cryo-electron microscopy revealed that autoantibodies in myasthenia gravis disrupt acetylcholine receptor function by blocking or activating the immune system's complement pathway. This knowledge helps explain treatment variability and offers a foundation for personalized therapies targeting specific antibody interactions.
A comprehensive review published in Brain Medicine maps out the extensive influence of reproductive hormones on neurological health and disease. The study examines how sex hormones affect a broad spectrum of neurological conditions, including vascular disorders, movement disorders, epilepsy, multiple sclerosis, and Alzheimer's disease.
The WISDOM project aims to integrate healthcare and research data to combat CIMDs through AI-driven models. The initiative hopes to improve disease diagnosis, treatment, and patient outcomes by sharing data securely across borders.
Researchers discovered a new treatment that strengthens muscles in patients with Myasthenia Gravis, an autoimmune disease leading to severe weakness and fatigue. The breakthrough, targeting the connection between nerves and muscle cells, shows promising results without significant side effects.
Cartesian Therapeutics has successfully treated patients with generalized myasthenia gravis using an RNA CAR-T therapy. The trial demonstrated marked and long-lasting clinical improvement, with three patients achieving complete or near-complete eradication of disease symptoms.
A small-scale clinical trial suggests a modified CAR-T therapy could effectively reduce myasthenia gravis symptoms, with three patients showing complete elimination of symptoms. The treatment was well-tolerated and has the potential for longer-lasting results compared to current treatments.
A randomized clinical trial found that rituximab significantly improved disease control in patients with new-onset myasthenia gravis, reducing the need for cortisone treatments and hospitalizations. The study's results offer hope for a more effective treatment strategy, but larger studies are needed to assess long-term effects.
Osaka University researchers identified medullary thymic epithelial cells (mTECs) expressing neuromuscular molecules in myasthenia gravis-thymoma samples. These findings suggest a new connection between the two diseases and may lead to novel therapeutic methods.
A new study of 181 patients found that about 15% test positive for one or both newly discovered antibodies that attack the point of communication between nerves and muscle. Those who tested positive tended to be sicker when diagnosed and have a more severe disease course.
Researchers found a 30% decrease in outpatient visits during the initial 10 weeks of the COVID-19 pandemic. The shift to virtual visits was partly offset by an increase in telephone and video visits, with over 10 million fewer in-person visits compared to previous years.
Researchers at George Washington University will establish a rare disease network for myasthenia gravis, focusing on basic and clinical investigators, patient advocacy groups, and biotechnology companies. The network aims to develop new therapies and increase awareness of the unique needs of myasthenia gravis patients.
University of Alberta researchers have identified a unique biological marker that can predict the course of myasthenia gravis and develop personalized treatment plans. The biomarker, composed of 12 metabolites exclusive to patients with myasthenia gravis, enables early diagnosis and more effective management of the disease.
Myasthenia gravis is a chronic autoimmune disorder that causes weakening of skeletal muscles. Researchers at Kanazawa University found that the immune system regulatory molecule programmed cell death ligand 1 (PD-1) is abundant in muscle tissue of patients, which may help reduce disease symptoms.
Researchers developed a 3-D crystal structure of the disease's molecular interactions with a neural receptor, providing a clear view of how it attacks and destroys proteins. The model could accelerate research and lead to new therapies for myasthenia gravis, which affects an estimated 36,000 to 60,000 Americans annually.
Researchers found that surgical removal of the thymus reduced patients' muscle weakness and their need for immunosuppressive drugs. The study also showed that surgery reduced the occurrence of adverse events and allowed patients to receive lower doses of prednisone.
A new study published in the New England Journal of Medicine found that thymectomy significantly improves disease status measures, reduces need for corticosteroids, and decreases hospitalization needs in MG patients without a chest tumor. This confirms the early use of thymectomy as an effective treatment option for MG.
Researchers are testing blood samples from patients with myasthenia gravis to determine the presence of two new antibodies, agrin and LRP4. The study aims to characterize their clinical symptoms and develop treatment strategies for double-negative patients.
A study of seven cases with severe myasthenia gravis found that autologous hematopoietic stem cell transplantation resulted in long-term symptom-free remission. The treatment was previously used for other autoimmune conditions, suggesting its potential as a therapy for MG.
A new study by George Washington University researchers found that autoimmune disorders and cancer share common pathogenic mechanisms. The study identified survivin as a key mediator of autoreactive cell survival in myasthenia gravis, an autoimmune disease that can lead to severe muscle weakness. The findings suggest a potential therap...
A fusion protein composed of scFv and human serum albumin has been developed to target the acetylcholine receptor in myasthenia gravis. The protein showed a high inhibition rate (2.0-77.4%) for binding to acetylcholine receptors, indicating potential therapeutic efficacy.
Scientists have discovered an antibody to the protein LRP4, which plays a critical role in enabling the brain to communicate with muscles. This finding explains why some patients with myasthenia gravis may not have any obvious signs of the disease despite having low levels of antibodies.
Researchers from FIGHT-MG project discover that a viral molecule can trigger an inappropriate immune response, causing muscular function to deteriorate. The study provides proof of concept that a viral infection can cause auto-immune myasthenia, a rare disease characterized by muscular weakness and exhaustion.
Johns Hopkins researchers have developed a gene-based therapy that specifically targets the immune response of myasthenia gravis, erasing the need for systemic immunosuppression. The technique uses genetically engineered dendritic cells to destroy faulty T-cells, reducing autoantibodies and halting the autoimmune attack.
Researchers have found a protein in tick saliva that works as a complement inhibitor, improving the health of rats with mild and severe models of myasthenia gravis. The protein, rEV576, may have therapeutic value in human myasthenia gravis and could offer a new treatment option with reduced side effects.
Researchers at SLU School of Medicine have found a way to prevent or reverse muscle weakness in myasthenia gravis by blocking the immune response that causes it. This breakthrough could lead to new treatments for related autoimmune disorders like arthritis and lupus.
A new oral treatment, EN101 antisense, has been shown to significantly reduce muscle weakness in people with myasthenia gravis. The study found that patients experienced improved muscle function, swallowing time, and disappearance of symptoms such as drooping eyelids.
Women with myasthenia gravis are at increased risk of complications during pregnancy and childbirth, including higher rates of cesarean section and preterm rupture of amniotic membranes. However, neonatal deaths and prematurity were not significantly affected by the condition.
Researchers are developing a new drug to treat myasthenia gravis by targeting the nerve-muscle communication point and reducing complement activation. The study aims to provide a more effective treatment with fewer side effects than existing therapies, which have limited success due to their adverse effects.
Researchers at the Weizmann Institute have developed a new treatment for a myasthenia gravis-like disease in rats by administering genetically engineered receptor fragments through the nose. The approach may serve as a basis for treating this autoimmune disease in humans, where symptoms can be life-threatening.